U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Approval Year

2011
587
Substance Class Protein
Created
by admin
on Mon Mar 31 18:34:17 GMT 2025
Edited
by admin
on Mon Mar 31 18:34:17 GMT 2025
Protein Type MONOCLONAL ANTIBODY CONJUGATE
Protein Sub Type IGG1|TOXIN CONJUGATE
Sequence Origin MOUSE CHIMERIC
Sequence Type COMPLETE
Record UNII
7XL5ISS668
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
BRENTUXIMAB VEDOTIN (GENETICAL RECOMBINATION)
JAN  
Preferred Name English
BRENTUXIMAB VEDOTIN
DASH   INN   MART.   MI   USAN   VANDF   WHO-DD  
USAN   INN  
Official Name English
BRENTUXIMAB VEDOTIN [VANDF]
Common Name English
SGN-35
Code English
Brentuximab vedotin [WHO-DD]
Common Name English
BRENTUXIMAB VEDOTIN [USAN]
Common Name English
BRENTUXIMAB VEDOTIN [PURPLE BOOK CDER]
Common Name English
BRENTUXIMAB [VANDF]
Common Name English
MAB CHIMERIC (IGG1) ANTI P28908 (TNR8_HUMAN) (SGN-35)
Common Name English
CAC10-VCMMAE
Code English
ADCETRIS
Brand Name English
BRENTUXIMAB VEDOTIN [JAN]
Common Name English
brentuximab vedotin [INN]
Common Name English
BRENTUXIMAB VEDOTIN [MART.]
Common Name English
BRENTUXIMAB VEDOTIN [MI]
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C1512
Created by admin on Mon Mar 31 18:34:17 GMT 2025 , Edited by admin on Mon Mar 31 18:34:17 GMT 2025
EU-Orphan Drug EU/3/11/939
Created by admin on Mon Mar 31 18:34:17 GMT 2025 , Edited by admin on Mon Mar 31 18:34:17 GMT 2025
FDA ORPHAN DRUG 362611
Created by admin on Mon Mar 31 18:34:17 GMT 2025 , Edited by admin on Mon Mar 31 18:34:17 GMT 2025
WHO-VATC QL01XC12
Created by admin on Mon Mar 31 18:34:17 GMT 2025 , Edited by admin on Mon Mar 31 18:34:17 GMT 2025
LIVERTOX NBK548844
Created by admin on Mon Mar 31 18:34:17 GMT 2025 , Edited by admin on Mon Mar 31 18:34:17 GMT 2025
LIVERTOX NBK548802
Created by admin on Mon Mar 31 18:34:17 GMT 2025 , Edited by admin on Mon Mar 31 18:34:17 GMT 2025
FDA ORPHAN DRUG 235606
Created by admin on Mon Mar 31 18:34:17 GMT 2025 , Edited by admin on Mon Mar 31 18:34:17 GMT 2025
FDA ORPHAN DRUG 418713
Created by admin on Mon Mar 31 18:34:17 GMT 2025 , Edited by admin on Mon Mar 31 18:34:17 GMT 2025
FDA ORPHAN DRUG 521716
Created by admin on Mon Mar 31 18:34:17 GMT 2025 , Edited by admin on Mon Mar 31 18:34:17 GMT 2025
EMA ASSESSMENT REPORTS ADCETRIS (AUTHORIZED: LYMPHOMA, NON-HODGKIN)
Created by admin on Mon Mar 31 18:34:17 GMT 2025 , Edited by admin on Mon Mar 31 18:34:17 GMT 2025
FDA ORPHAN DRUG 656818
Created by admin on Mon Mar 31 18:34:17 GMT 2025 , Edited by admin on Mon Mar 31 18:34:17 GMT 2025
FDA ORPHAN DRUG 394013
Created by admin on Mon Mar 31 18:34:17 GMT 2025 , Edited by admin on Mon Mar 31 18:34:17 GMT 2025
FDA ORPHAN DRUG 528716
Created by admin on Mon Mar 31 18:34:17 GMT 2025 , Edited by admin on Mon Mar 31 18:34:17 GMT 2025
FDA ORPHAN DRUG 550916
Created by admin on Mon Mar 31 18:34:17 GMT 2025 , Edited by admin on Mon Mar 31 18:34:17 GMT 2025
EMA ASSESSMENT REPORTS ADCETRIS (AUTHORIZED: HODGKIN DISEASE)
Created by admin on Mon Mar 31 18:34:17 GMT 2025 , Edited by admin on Mon Mar 31 18:34:17 GMT 2025
FDA ORPHAN DRUG 536516
Created by admin on Mon Mar 31 18:34:17 GMT 2025 , Edited by admin on Mon Mar 31 18:34:17 GMT 2025
FDA ORPHAN DRUG 404913
Created by admin on Mon Mar 31 18:34:17 GMT 2025 , Edited by admin on Mon Mar 31 18:34:17 GMT 2025
FDA ORPHAN DRUG 268908
Created by admin on Mon Mar 31 18:34:17 GMT 2025 , Edited by admin on Mon Mar 31 18:34:17 GMT 2025
NDF-RT N0000182967
Created by admin on Mon Mar 31 18:34:17 GMT 2025 , Edited by admin on Mon Mar 31 18:34:17 GMT 2025
WHO-ATC L01XC12
Created by admin on Mon Mar 31 18:34:17 GMT 2025 , Edited by admin on Mon Mar 31 18:34:17 GMT 2025
NCI_THESAURUS C129823
Created by admin on Mon Mar 31 18:34:17 GMT 2025 , Edited by admin on Mon Mar 31 18:34:17 GMT 2025
Code System Code Type Description
LACTMED
Brentuximab Vedotin
Created by admin on Mon Mar 31 18:34:17 GMT 2025 , Edited by admin on Mon Mar 31 18:34:17 GMT 2025
PRIMARY
EVMPD
SUB32397
Created by admin on Mon Mar 31 18:34:17 GMT 2025 , Edited by admin on Mon Mar 31 18:34:17 GMT 2025
PRIMARY
SMS_ID
100000124524
Created by admin on Mon Mar 31 18:34:17 GMT 2025 , Edited by admin on Mon Mar 31 18:34:17 GMT 2025
PRIMARY
DRUG BANK
DB08870
Created by admin on Mon Mar 31 18:34:17 GMT 2025 , Edited by admin on Mon Mar 31 18:34:17 GMT 2025
PRIMARY
NCI_THESAURUS
C66944
Created by admin on Mon Mar 31 18:34:17 GMT 2025 , Edited by admin on Mon Mar 31 18:34:17 GMT 2025
PRIMARY
WIKIPEDIA
BRENTUXIMAB VEDOTIN
Created by admin on Mon Mar 31 18:34:17 GMT 2025 , Edited by admin on Mon Mar 31 18:34:17 GMT 2025
PRIMARY
INN
9144
Created by admin on Mon Mar 31 18:34:17 GMT 2025 , Edited by admin on Mon Mar 31 18:34:17 GMT 2025
PRIMARY
MERCK INDEX
m2645
Created by admin on Mon Mar 31 18:34:17 GMT 2025 , Edited by admin on Mon Mar 31 18:34:17 GMT 2025
PRIMARY Merck Index
MESH
C547738
Created by admin on Mon Mar 31 18:34:17 GMT 2025 , Edited by admin on Mon Mar 31 18:34:17 GMT 2025
PRIMARY
NDF-RT
N0000182966
Created by admin on Mon Mar 31 18:34:17 GMT 2025 , Edited by admin on Mon Mar 31 18:34:17 GMT 2025
PRIMARY CD30-directed Antibody Interactions [MoA]
IUPHAR
6772
Created by admin on Mon Mar 31 18:34:17 GMT 2025 , Edited by admin on Mon Mar 31 18:34:17 GMT 2025
PRIMARY
ChEMBL
CHEMBL1742994
Created by admin on Mon Mar 31 18:34:17 GMT 2025 , Edited by admin on Mon Mar 31 18:34:17 GMT 2025
PRIMARY
CAS
914088-09-8
Created by admin on Mon Mar 31 18:34:17 GMT 2025 , Edited by admin on Mon Mar 31 18:34:17 GMT 2025
PRIMARY
RXCUI
1147320
Created by admin on Mon Mar 31 18:34:17 GMT 2025 , Edited by admin on Mon Mar 31 18:34:17 GMT 2025
PRIMARY RxNorm
DRUG CENTRAL
4964
Created by admin on Mon Mar 31 18:34:17 GMT 2025 , Edited by admin on Mon Mar 31 18:34:17 GMT 2025
PRIMARY
DAILYMED
7XL5ISS668
Created by admin on Mon Mar 31 18:34:17 GMT 2025 , Edited by admin on Mon Mar 31 18:34:17 GMT 2025
PRIMARY
FDA UNII
7XL5ISS668
Created by admin on Mon Mar 31 18:34:17 GMT 2025 , Edited by admin on Mon Mar 31 18:34:17 GMT 2025
PRIMARY
JAPANESE REVIEW
ADCETRIS
Created by admin on Mon Mar 31 18:34:17 GMT 2025 , Edited by admin on Mon Mar 31 18:34:17 GMT 2025
PRIMARY APPROVED JANUARY 2014
USAN
UU-153
Created by admin on Mon Mar 31 18:34:17 GMT 2025 , Edited by admin on Mon Mar 31 18:34:17 GMT 2025
PRIMARY
From To
1_22 1_96
1_144 1_200
1_220 3_218
1_226 2_226
1_229 2_229
1_261 1_321
1_367 1_425
2_22 2_96
2_144 2_200
2_220 4_218
2_261 2_321
2_367 2_425
3_23 3_92
3_138 3_198
4_23 4_92
4_138 4_198
Glycosylation Type MAMMALIAN
Glycosylation Link Type Site
N 1_297
N 2_297
Related Record Type Details
Structure of VEDOTIN FRAGMENT
CONJUGATE COMPONENT->CONJUGATE
TUMOR NECROSIS FACTOR RECEPTOR SUPERFAMILY MEMBER 8
TARGET->CONJUGATED TOXIN
The Kd for the 3 lots ranged from 1.92 +/- 0.77 to 2.64 +/- 0.94 nM. The Kd for the cAC10, the unconjugated antibody, was 1.38.
BINDING
Kd
TUMOR NECROSIS FACTOR RECEPTOR SUPERFAMILY MEMBER 8
TARGET -> INHIBITOR
Related Record Type Details
Structure of MONOMETHYL AURISTATIN E
METABOLITE ACTIVE -> PARENT
Addition of E64d, a cysteine protease inhibitor, blocked the release of MMAE
FECAL; URINE
Related Record Type Details
BRENTUXIMAB VEDOTIN
ACTIVE MOIETY

Structural Modifications

Modification Type Location Site Location Type Residue Modified Extent Fragment Name Fragment Approval
AMINO ACID SUBSTITUTION [1_1] [2_1] SITE_SPECIFIC GLUTAMINE Amount: PIDOLIC ACID SZB83O1W42
AMINO_ACID_SUBSTITUTION RESIDUE_SPECIFIC C Amount: Cysteinyl vedotin 6603L01WUR
Name Property Type Amount Referenced Substance Defining Parameters References
MOL_WEIGHT:NUMBER(CALCULATED) CHEMICAL
Molecular Formula CHEMICAL
NIH
NCATS
PRIVACY NOTICE
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966